A recent subgroup analysis of the DAPA-HF study investigated possible clinical outcome differences between women and men following the addition of dapagliflozin to their treatment regimens.
Women and men with heart failure with reduced ejection fraction (HFrEF)—all participants in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial—similarly benefited from the addition of dapagliflozin to their treatment regimens.
Diabetes status did not affect these results, according to the findings published recently in JAMA Cardiology.
Women with HF generally have a greater disease burden and they have been shown to benefit less from treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors, of which dapagliflozin is one. However, this class has also proven itself in recent years as “a valuable treatment for HFrEF, and it is clearly important to examine the effects of this therapy in women as well as men with HFrEF,” the authors noted.
The 4744 patients included in this analysis (23.4% women), with a primary outcome of worsening HF (eg, hospitalization or urgent visit with intravenous therapy) or cardiovascular death, had New York Heart Association functional class II through IV disease and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. They were randomized to an addition of either 10-mg one-daily dapagliflozin or placebo.
Dapagliflozin was shown to similarly lessen the risk of worsening HF events or CV death in men and women:
The SGLT2 inhibitor also resulted in there being more patients with meaningful symptom improvement and fewer with worsening symptoms vs placebo, respectively, as measured by the Kansas City Cardiomyopathy Questionnaire total symptom score:
Treatment discontinuation and the rate of serious adverse events, too, were consistent among the men (mean [SD] age, 65.9 [10.9] years) and women (mean age, 67.6 [10.7] years).
The women in the study tended to be older and Black. They also had a lesser likelihood of atrial fibrillation, chronic obstructive pulmonary disease, and anemia, but a greater chance of having higher systolic blood pressure, heart rate, and baseline NT-proBNP.
Analyses also found:
In addition, systolic blood pressure similarly decreased in both patient groups. At the 4-month mark, this amounted to –1.69 mm Hg (95% CI, –3.37 to –0.02) for the women and –1.88 mm Hg (95% CI, –2.80 to –0.96) for the men.
“Dapagliflozin reduced the risk of worsening HF, cardiovascular death, and all-cause death and improved symptoms, physical function, and health-related quality of life similarly in men and women with heart failure and reduced ejection fraction,” the authors concluded. “Collectively, these data provide further support for dapagliflozin as a new treatment option for HFrEF.”
Importantly, the authors highlight that their finding should offer reassurance that dapagliflozin is tolerable and safe for use among patients with HFrEF, women and men.
Reference
Butt JH, Docherty KF, Petrie MC, et al. Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JAMA Cardiol. Published online March 31, 2021. doi:10.1001/jamacardio.2021.0379
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More